https://orcid.org/0000-0002-9359-1203
Key Points
Geriatric assessments can aid in identifying patients with less physical resilience who are at increased risk of grade ≥3 adverse events.
Fixed-duration Ven-O improves HRQoL in patients with CLL with and without geriatric impairments.
Abstract
Chronic lymphocytic leukemia (CLL)–related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67). However, prolonged venetoclax exposure as consolidation treatment led to increased toxicity with limited effect on minimal residual disease. To assess the impact of geriatric assessment on treatment outcomes and the patients’ HRQoL, patient-reported outcomes (PROs), including function, depression, cognition, nutrition, physical performance, muscle parameters, comorbidities, and the European Organization for Research and Treatment of Cancer C30 and CLL17 questionnaires were assessed. At baseline, geriatric impairments were present in >90% of patients and ≥2 impairments present in 60% of patients predicted grade ≥3 nonhematological toxicity. During treatment, the number of geriatric impairments diminished significantly and clinically relevant improvements in HRQoL subscales were reached for global health status, physical functioning, role functioning, emotional functioning, fatigue, dyspnea, physical condition or fatigue, and worries or fears related to health and functioning. These improvements were comparable for patients receiving venetoclax consolidation and patients in whom treatment could mostly be discontinued. Collectively, frontline fixed-duration Ven-O improves overall PROs in older, unfit patients with CLL with and without geriatric impairments. This study was registered at EudraCT as 2015-004985-27 and the Netherlands Trial Register as NTR6043.
References
1.
van der Straten
L
, Levin
M-D
, Visser
O
, et al. Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016
. Br J Haematol
. 2020
;189
(3
):574
-577
.2.
da Cunha-Bang
C
, Simonsen
J
, Rostgaard
K
, Geisler
C
, Hjalgrim
H
, Niemann
CU
. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients
. Blood Cancer J
. 2016
;6
(11
):e499
.3.
Steingrímsson
V
, Lund
SH
, Dickman
PW
, et al. Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: a population-based study
. Eur J Haematol
. 2022
;108
(2
):145
-153
.4.
Kristinsson
SY
, Dickman
PW
, Wilson
WH
, Caporaso
N
, Björkholm
M
, Landgren
O
. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden
. Haematologica
. 2009
;94
(9
):1259
-1265
.5.
Molica
S
, Giannarelli
D
, Levato
L
, et al. A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients
. Leuk Lymphoma
. 2019
;60
(3
):845
-847
.6.
Goede
V
, Bahlo
J
, Chataline
V
, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group
. Leuk Lymphoma
. 2016
;57
(4
):789
-796
.7.
Scheepers
ERM
, Vondeling
AM
, Thielen
N
, van der Griend
R
, Stauder
R
, Hamaker
ME
. Geriatric assessment in older patients with a hematologic malignancy: a systematic review
. Haematologica
. 2020
;105
(6
):1484
-1493
.8.
Stauder
R
, Eichhorst
B
, Hamaker
M
, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an International Society of Geriatric Oncology (SIOG) Task Force
. Ann Oncol
. 2017
;28
(2
):218
-227
.9.
Woyach
JA
, Ruppert
AS
, Heerema
NA
, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
. N Engl J Med
. 2018
;379
(26
):2517
-2528
.10.
Al-Sawaf
O
, Zhang
C
, Tandon
M
, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
. Lancet Oncol
. 2020
;21
(9
):1188
-1200
.11.
Burger
JA
, Tedeschi
A
, Barr
PM
, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
. N Engl J Med
. 2015
;373
(25
):2425
-2437
.12.
Byrd
JC
, Brown
JR
, O'brien
S
, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
. N Engl J Med
. 2014
;371
(3
):213
-223
.13.
Munir
T
, Brown
JR
, O'Brien
S
, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
. Am J Hematol
. 2019
;94
(12
):1353
-1363
.14.
O'Brien
SM
, Lamanna
N
, Kipps
TJ
, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
. Blood
. 2015
;126
(25
):2686
-2694
.15.
Furman
RR
, Sharman
JP
, Coutre
SE
, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
. N Engl J Med
. 2014
;370
(11
):997
-1007
.16.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
. Lancet
. 2020
;395
(10232
):1278
-1291
.17.
Ghia
P
, Pluta
A
, Wach
M
, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia
. J Clin Oncol
. 2020
;38
(25
):2849
-2861
.18.
Stilgenbauer
S
, Eichhorst
B
, Schetelig
J
, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
. Lancet Oncol
. 2016
;17
(6
):768
-778
.19.
Kater
AP
, Wu
JQ
, Kipps
T
, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study
. J Clin Oncol
. 2020
;38
(34
):4042
-4054
.20.
Seymour
JF
, Kipps
TJ
, Eichhorst
B
, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
. N Engl J Med
. 2018
;378
(12
):1107
-1120
.21.
Xu
W
, Yang
S
, Zhou
K
, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
. J Hematol Oncol
. 2020
;13
:48
.22.
Tam
CS
, Robak
T
, Ghia
P
, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion
. Haematologica
. 2020
;106
(9
):2354
-2363
.23.
Mato
AR
, Shah
NN
, Jurczak
W
, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
. Lancet
. 2021
;397
(10277
):892
-901
.24.
Goede
V
, Fischer
K
, Busch
R
, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
. N Engl J Med
. 2014
;370
(12
):1101
-1110
.25.
Michallet
A-S
, Aktan
M
, Hiddemann
W
, et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
. Haematologica
. 2018
;103
(4
):698
-706
.26.
Kersting
S
, Dubois
J
, Nasserinejad
K
, et al. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
. Lancet Haematol
. 2022
;9
(3
):e190
-e199
.27.
van der Straten
L
, Maas
CCHM
, Levin
M-D
, et al. Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989–2018
. Blood Cancer J
. 2022
;12
(4
):72
.28.
Hallek
M
, Cheson
BD
, Catovsky
D
, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia
. Blood
. 2018
;131
(25
):2745
-2760
.29.
Charlson
ME
, Pompei
P
, Ales
KL
, MacKenzie
CR
. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
. J Chronic Dis
. 1987
;40
(5
):373
-383
.30.
Katz
S
. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living
. J Am Geriatr Soc
. 1983
;31
(12
):721
-727
.31.
Lawton
M
. Scales to measure competence in everyday activities
. Psychopharmacol Bull
. 1988
;24
(4
):609
-614
.32.
Shelk
J
, Yesavage
J
. Geriatric depression rating scale (GDS): recent evidence and a shorter version. In: Brink
TL
, eds. Clinical Gerontology: A Guide to Assessment and Intervention
. Haworth Press
; 1986
:165
-173
.33.
Rubenstein
LZ
, Harker
JO
, Salvà
A
, Guigoz
Y
, Vellas
B
. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF)
. J Gerontol A Biol Sci Med Sci
. 2001
;56
(6
):M366
-M372
.34.
Folstein
MF
, Folstein
SE
, McHugh
PR
. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician
. J Psychiatr Res
. 1975
;12
(3
):189
-198
.35.
Cruz-Jentoft
AJ
, Bahat
G
, Bauer
J
, et al. Sarcopenia: revised European consensus on definition and diagnosis
. Age Ageing
. 2019
;48
(1
):16
-31
.36.
Cruz-Jentoft
AJ
, Baeyens
JP
, Bauer
JM
, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People
. Age Ageing
. 2010
;39
(4
):412
-423
.37.
Aaronson
NK
, Ahmedzai
S
, Bergman
B
, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
. J Natl Cancer Inst
. 1993
;85
(5
):365
-376
.38.
van de Poll-Franse
L
, Oerlemans
S
, Bredart
A
, et al. International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high-and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia
. Qual Life Res
. 2018
;27
(2
):333
-345
.39.
Fayers
P
, Aaronson
NK
, Bjordal
K
, Sullivan
M
. EORTC QLQ–C30 Scoring Manual. European Organisation for Research and Treatment of Cancer
; 1995
.40.
Wyrwich
KW
, Tierney
WM
, Wolinsky
FD
. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life
. J Clin Epidemiol
. 1999
;52
(9
):861
-873
.41.
Cohen
J
. Statistical power analysis for the behavioral sciences. Routledge
; 2013
.42.
King
MT
. A point of minimal important difference (MID): a critique of terminology and methods
. Expert Rev Pharmacoecon Outcomes Res
. 2011
;11
(2
):171
-184
.43.
Cocks
K
, King
MT
, Velikova
G
, Martyn St-James
M
, Fayers
PM
, Brown
JM
. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
. J Clin Oncol
. 2011
;29
(1
):89
-96
.44.
Cocks
K
, King
M
, Velikova
G
, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
. Eur J Cancer
. 2012
;48
(11
):1713
-1721
.45.
Nielsen
LK
, Stege
C
, Lissenberg-Witte
B
, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
. Haematologica
. 2020
;105
(6
):1650
-1659
.46.
Stein
KD
, Smith
T
, Bauer
JE
, Driscoll
DL
, Cooper
DL
. Patient-reported outcomes in cancer: application and utility in clinical practice and research. The American Cancer Society's Principles of Oncology: Prevention to Survivorship
. Wiley
; 2018
:409
-418
.47.
Hwang
TJ
, Gyawali
B
. Association between progression-free survival and patients’ quality of life in cancer clinical trials
. Int J Cancer
. 2019
;144
(7
):1746
-1751
.48.
Howell
D
, Molloy
S
, Wilkinson
K
, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors
. Ann Oncol
. 2015
;26
(9
):1846
-1858
.49.
LeBlanc
TW
, Abernethy
AP
. Patient-reported outcomes in cancer care—hearing the patient voice at greater volume
. Nat Rev Clin Oncol
. 2017
;14
(12
):763
-772
.50.
Wildiers
H
, Heeren
P
, Puts
M
, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer
. J Clin Oncol
. 2014
;32
(24
):2595
-2603
.51.
Tucci
A
, Ferrari
S
, Bottelli
C
, Borlenghi
E
, Drera
M
, Rossi
G
. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy
. Cancer
. 2009
;115
(19
):4547
-4553
.52.
Wildes
TM
, Ruwe
AP
, Fournier
C
, et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer
. J Geriatr Oncol
. 2013
;4
(3
):227
-234
.53.
Palumbo
A
, Bringhen
S
, Mateos
M-V
, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
. Blood
. 2015
;125
(13
):2068
-2074
.54.
Shanafelt
TD
, Bowen
D
, Venkat
C
, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients
. Br J Haematol
. 2007
;139
(2
):255
-264
.55.
van den Broek
EC
, Oerlemans
S
, Nijziel
MR
, Posthuma
EF
, Coebergh
JW
, van de Poll-Franse
LV
. Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands
. Ann Hematol
. 2015
;94
(1
):45
-56
.56.
Holtzer-Goor
KM
, Schaafsma
MR
, Joosten
P
, et al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study
. Qual Life Res
. 2015
;24
(12
):2895
-2906
.57.
Burger
JA
, Barr
PM
, Robak
T
, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
. Leukemia
. 2020
;34
(3
):787
-798
.58.
Youron
P
, Singh
C
, Jindal
N
, et al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire
. Eur J Haematol
. 2020
;105
(6
):755
-762
.59.
Cochrane
T
, Chagorova
T
, Robak
T
, et al. Venetoclax improves quality of life for patients with elapsed/refractory chronic lymphocytic leukemia [abstract]
. Blood
. 2018
;132
(suppl 1
):4858
.60.
Kutsch
N
, Bahlo
J
, Robrecht
S
, et al. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 Trial of the GCLLSG)
. Hemasphere
. 2020
;4
(1
):e336
.61.
Ghia
P
, Coutre
SE
, Cheson
BD
, et al. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
. Haematologica
. 2020
;105
(10
):e519
.62.
Eichhorst
BF
, Busch
R
, Obwandner
T
, Kuhn-Hallek
I
, Herschbach
P
, Hallek
M
; German CLL Study Group
. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group
. J Clin Oncol
. 2007
;25
(13
):1722
-1731
.63.
Else
M
, Cocks
K
, Crofts
S
, et al. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial
. Leuk Lymphoma
. 2012
;53
(7
):1289
-1298
.64.
Al-Sawaf
O
, Gentile
B
, Devine
J
, et al. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: results from the randomized, phase 3 CLL14 trial
. Am J Hematol
. 2021
;96
(9
):1112
-1119
.65.
Swash
B
, Bramwell
R
, Hulbert-Williams
NJ
. Unmet psychosocial supportive care needs and psychological distress in haematological cancer survivors: the moderating role of psychological flexibility
. J Context Behav Sci
. 2017
;6
(2
):187
-194
.© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal